Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Urogenital Neoplasms --- Immunotherapy. --- Neoadjuvant Therapy. --- Genitourinary organs --- therapy. --- Cancer --- Adjuvant treatment. --- Neoadjuvant Chemoradiation --- Neoadjuvant Chemoradiation Therapy --- Neoadjuvant Chemoradiation Treatment --- Neoadjuvant Chemoradiotherapy --- Neoadjuvant Chemotherapy --- Neoadjuvant Chemotherapy Treatment --- Neoadjuvant Radiation --- Neoadjuvant Radiation Therapy --- Neoadjuvant Radiation Treatment --- Neoadjuvant Radiotherapy --- Neoadjuvant Systemic Therapy --- Neoadjuvant Systemic Treatment --- Neoadjuvant Treatment --- Chemoradiation Therapy, Neoadjuvant --- Chemoradiation Treatment, Neoadjuvant --- Chemoradiation, Neoadjuvant --- Chemoradiotherapy, Neoadjuvant --- Chemotherapy Treatment, Neoadjuvant --- Chemotherapy, Neoadjuvant --- Neoadjuvant Chemoradiation Therapies --- Neoadjuvant Chemoradiation Treatments --- Neoadjuvant Chemoradiations --- Neoadjuvant Chemoradiotherapies --- Neoadjuvant Chemotherapies --- Neoadjuvant Chemotherapy Treatments --- Neoadjuvant Radiation Therapies --- Neoadjuvant Radiation Treatments --- Neoadjuvant Radiations --- Neoadjuvant Radiotherapies --- Neoadjuvant Systemic Therapies --- Neoadjuvant Systemic Treatments --- Neoadjuvant Therapies --- Neoadjuvant Treatments --- Radiation Therapy, Neoadjuvant --- Radiation Treatment, Neoadjuvant --- Radiation, Neoadjuvant --- Radiotherapy, Neoadjuvant --- Systemic Therapy, Neoadjuvant --- Systemic Treatment, Neoadjuvant --- Therapy, Neoadjuvant --- Therapy, Neoadjuvant Chemoradiation --- Therapy, Neoadjuvant Radiation --- Therapy, Neoadjuvant Systemic --- Treatment, Neoadjuvant --- Treatment, Neoadjuvant Chemoradiation --- Treatment, Neoadjuvant Chemotherapy --- Treatment, Neoadjuvant Radiation --- Treatment, Neoadjuvant Systemic --- Immunotherapies --- Combined Antibody Therapeutics --- Immunity, Active --- Immunologic Techniques --- Càncer genitourinari --- Tractament adjuvant del càncer --- Immunoteràpia

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Breast --- Neoadjuvant Therapy. --- Breast Neoplasms. --- Sentinel Lymph Node. --- Axilla. --- Cancer --- Surgery. --- Armpit --- Underarm --- Sentinal Node --- Lymph Node, Sentinel --- Lymph Nodes, Sentinel --- Node, Sentinal --- Nodes, Sentinal --- Sentinal Nodes --- Sentinel Lymph Nodes --- Lymphatic Metastasis --- Sentinel Lymph Node Biopsy --- Breast Carcinoma --- Cancer of the Breast --- Human Mammary Carcinoma --- Malignant Neoplasm of Breast --- Malignant Tumor of Breast --- Mammary Cancer --- Mammary Carcinoma, Human --- Mammary Neoplasm, Human --- Mammary Neoplasms, Human --- Neoplasms, Breast --- Tumors, Breast --- Breast Cancer --- Breast Tumors --- Cancer of Breast --- Breast Carcinomas --- Breast Malignant Neoplasm --- Breast Malignant Neoplasms --- Breast Malignant Tumor --- Breast Malignant Tumors --- Breast Neoplasm --- Breast Tumor --- Cancer, Breast --- Cancer, Mammary --- Cancers, Mammary --- Carcinoma, Breast --- Carcinoma, Human Mammary --- Carcinomas, Breast --- Carcinomas, Human Mammary --- Human Mammary Carcinomas --- Human Mammary Neoplasm --- Human Mammary Neoplasms --- Mammary Cancers --- Mammary Carcinomas, Human --- Neoplasm, Breast --- Neoplasm, Human Mammary --- Neoplasms, Human Mammary --- Tumor, Breast --- Breast Cancer Lymphedema --- Neoadjuvant Chemoradiation --- Neoadjuvant Chemoradiation Therapy --- Neoadjuvant Chemoradiation Treatment --- Neoadjuvant Chemoradiotherapy --- Neoadjuvant Chemotherapy --- Neoadjuvant Chemotherapy Treatment --- Neoadjuvant Radiation --- Neoadjuvant Radiation Therapy --- Neoadjuvant Radiation Treatment --- Neoadjuvant Radiotherapy --- Neoadjuvant Systemic Therapy --- Neoadjuvant Systemic Treatment --- Neoadjuvant Treatment --- Chemoradiation Therapy, Neoadjuvant --- Chemoradiation Treatment, Neoadjuvant --- Chemoradiation, Neoadjuvant --- Chemoradiotherapy, Neoadjuvant --- Chemotherapy Treatment, Neoadjuvant --- Chemotherapy, Neoadjuvant --- Neoadjuvant Chemoradiation Therapies --- Neoadjuvant Chemoradiation Treatments --- Neoadjuvant Chemoradiations --- Neoadjuvant Chemoradiotherapies --- Neoadjuvant Chemotherapies --- Neoadjuvant Chemotherapy Treatments --- Neoadjuvant Radiation Therapies --- Neoadjuvant Radiation Treatments --- Neoadjuvant Radiations --- Neoadjuvant Radiotherapies --- Neoadjuvant Systemic Therapies --- Neoadjuvant Systemic Treatments --- Neoadjuvant Therapies --- Neoadjuvant Treatments --- Radiation Therapy, Neoadjuvant --- Radiation Treatment, Neoadjuvant --- Radiation, Neoadjuvant --- Radiotherapy, Neoadjuvant --- Systemic Therapy, Neoadjuvant --- Systemic Treatment, Neoadjuvant --- Therapy, Neoadjuvant --- Therapy, Neoadjuvant Chemoradiation --- Therapy, Neoadjuvant Radiation --- Therapy, Neoadjuvant Systemic --- Treatment, Neoadjuvant --- Treatment, Neoadjuvant Chemoradiation --- Treatment, Neoadjuvant Chemotherapy --- Treatment, Neoadjuvant Radiation --- Treatment, Neoadjuvant Systemic --- Càncer de mama --- Cirurgia

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Gastrointestinal (GI) cancer is a major cause of morbidity and mortality in the world. Since early diagnosis and optimal treatment selection are crucial to improving the prognosis of these diseases, the discovery of useful biomarkers has the potential to greatly reduce their burden. Recent technical and mechanical developments have allowed for the detection of tiny differences in various factors modified in physical conditions, which could contribute to the discovery of novel biomarkers for some diseases.In this Special Issue, we aim to focus on novel biomarkers for GI cancers, including esophageal cancer, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer and biliary cancer. In addition, any samples (tissue, blood, urine and feces) are useful as biomarker sources, although body-fluid-based biomarkers are promising as diagnostic biomarkers due to their noninvasiveness. This Special Issue aims to collect novel insights clarifying the current situation and future perspective in this field.

Medicine --- Oncology --- colorectal cancer --- advanced adenoma --- screening --- stool --- mRNA --- cancer screening --- cirrhosis --- AFP --- machine learning --- MALDI-TOF --- proteomics --- CXCR4 --- prognosis --- overall survival --- rectal cancer --- neoadjuvant chemoradiation --- mouse model --- biomarkers --- urokinase plasminogen activator (uPA) --- urokinase plasminogen activator receptor (uPAR) --- plasminogen activator inhibitor type 1 (PAI-1) --- circulating tumour cell (CTC) --- gastric cancer --- oesophageal cancer --- serine proteases --- tumour microenvironment --- serpins --- biomarker --- chemoresistance --- liquid biopsy --- microRNA --- long non-coding RNA --- colorectal neoplasms --- cancer screening tests --- early detection of cancer --- precision medicine --- unfolded protein --- hepatocellular cancer --- GSVA --- unfolded protein score --- epigenetic regulation genes --- somatic mutations --- molecular genetic markers --- extracellular vesicles --- microbiome --- 16S rRNA amplicon --- metagenomics --- liver fibrosis --- hepatocellular carcinoma --- recurrence --- SHG/TPEF microscopy --- artificial intelligence --- advanced gastric cancer --- targeted therapy --- urinary miRNA --- miR-129-1-3p --- miR-566 --- colorectal cancer --- advanced adenoma --- screening --- stool --- mRNA --- cancer screening --- cirrhosis --- AFP --- machine learning --- MALDI-TOF --- proteomics --- CXCR4 --- prognosis --- overall survival --- rectal cancer --- neoadjuvant chemoradiation --- mouse model --- biomarkers --- urokinase plasminogen activator (uPA) --- urokinase plasminogen activator receptor (uPAR) --- plasminogen activator inhibitor type 1 (PAI-1) --- circulating tumour cell (CTC) --- gastric cancer --- oesophageal cancer --- serine proteases --- tumour microenvironment --- serpins --- biomarker --- chemoresistance --- liquid biopsy --- microRNA --- long non-coding RNA --- colorectal neoplasms --- cancer screening tests --- early detection of cancer --- precision medicine --- unfolded protein --- hepatocellular cancer --- GSVA --- unfolded protein score --- epigenetic regulation genes --- somatic mutations --- molecular genetic markers --- extracellular vesicles --- microbiome --- 16S rRNA amplicon --- metagenomics --- liver fibrosis --- hepatocellular carcinoma --- recurrence --- SHG/TPEF microscopy --- artificial intelligence --- advanced gastric cancer --- targeted therapy --- urinary miRNA --- miR-129-1-3p --- miR-566

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The road of acceptance of oncologic thermotherapy/hyperthermia as a synergistic modality in combination with standard oncologic therapies is still bumpy. This is partially due to the lack of level I evidence from international, multicentric, randomized clinical trials including large patient numbers and a long term follow-up. Therefore we need more level I EVIDENCE from clinical trials, we need HARMONISATION and global acceptance for existing technologies and a common language understood by all stakeholders and we need INNOVATION in the fields of biology, clinics and technology to move thermotherapy/hyperthermia forward. This is the main focus of this reprint. In this reprintyou find carefully selected and peer-reviewed contributions from Africa, America, Asia, and Europe. The published papers from leading scientists from all over the world covering a broad range of timely research topics might also help to strengthen thermotherapy on a global level.

Medicine --- Oncology --- perfusion estimation --- temperature monitoring --- conductivity reconstruction --- systems medicine --- immune system in silico --- perceptron --- antigen pattern --- danger signal --- fractionation --- immune response --- head and neck cancer --- hyperthermia --- reirradiation --- treatment outcome --- hyperthermia treatment planning --- adaptive planning --- temperature optimization --- low-middle-income group countries --- cancer --- radiotherapy --- chemotherapy --- recurrent breast cancers --- cervical cancer --- head and neck cancers --- cost-effective --- meta-analysis --- intensity-modulated radiotherapy --- prostate cancer --- thermal dose --- thermometric parameters --- preclinical data --- clinical evidence --- modulated electro-hyperthermia --- abscopal effect --- locally advanced cervical cancer --- resource-constrained setting --- radiosensitiser --- rectal cancer --- chemoradiotherapy --- tumour control --- loco-regional hyperthermia --- oncology --- cellular selection --- bioelectromagnetics --- complexity --- immune-effects --- moderate hyperthermia --- deep hyperthermia --- radiative hyperthermia --- patterns of care --- reimbursement --- regional hyperthermia --- neoadjuvant chemoradiation --- survival --- induced --- brachytherapy --- prostatic neoplasms --- interstitial hyperthermia --- treatment plan optimization --- prostate --- thermoradiotherapy --- linear quadratic model --- biological modeling --- thermal dosimetry --- hypoxia --- radiation therapy --- reoxygenation --- perfusion --- oxygen consumption rate --- local tumor control --- biomarker --- immune phenotype --- hyperthermia treatment sequence --- breast cancer --- immune checkpoint molecules --- dendritic cell activation --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The road of acceptance of oncologic thermotherapy/hyperthermia as a synergistic modality in combination with standard oncologic therapies is still bumpy. This is partially due to the lack of level I evidence from international, multicentric, randomized clinical trials including large patient numbers and a long term follow-up. Therefore we need more level I EVIDENCE from clinical trials, we need HARMONISATION and global acceptance for existing technologies and a common language understood by all stakeholders and we need INNOVATION in the fields of biology, clinics and technology to move thermotherapy/hyperthermia forward. This is the main focus of this reprint. In this reprintyou find carefully selected and peer-reviewed contributions from Africa, America, Asia, and Europe. The published papers from leading scientists from all over the world covering a broad range of timely research topics might also help to strengthen thermotherapy on a global level.

perfusion estimation --- temperature monitoring --- conductivity reconstruction --- systems medicine --- immune system in silico --- perceptron --- antigen pattern --- danger signal --- fractionation --- immune response --- head and neck cancer --- hyperthermia --- reirradiation --- treatment outcome --- hyperthermia treatment planning --- adaptive planning --- temperature optimization --- low-middle-income group countries --- cancer --- radiotherapy --- chemotherapy --- recurrent breast cancers --- cervical cancer --- head and neck cancers --- cost-effective --- meta-analysis --- intensity-modulated radiotherapy --- prostate cancer --- thermal dose --- thermometric parameters --- preclinical data --- clinical evidence --- modulated electro-hyperthermia --- abscopal effect --- locally advanced cervical cancer --- resource-constrained setting --- radiosensitiser --- rectal cancer --- chemoradiotherapy --- tumour control --- loco-regional hyperthermia --- oncology --- cellular selection --- bioelectromagnetics --- complexity --- immune-effects --- moderate hyperthermia --- deep hyperthermia --- radiative hyperthermia --- patterns of care --- reimbursement --- regional hyperthermia --- neoadjuvant chemoradiation --- survival --- induced --- brachytherapy --- prostatic neoplasms --- interstitial hyperthermia --- treatment plan optimization --- prostate --- thermoradiotherapy --- linear quadratic model --- biological modeling --- thermal dosimetry --- hypoxia --- radiation therapy --- reoxygenation --- perfusion --- oxygen consumption rate --- local tumor control --- biomarker --- immune phenotype --- hyperthermia treatment sequence --- breast cancer --- immune checkpoint molecules --- dendritic cell activation --- n/a